Affymetrix Inc. Sets New 1-Year High at $8.99 (AFFX)
Affymetrix (NASDAQ:AFFX) set a new 52-week high during mid-day trading on Wednesday, Stock Ratings Network reports. The stock traded as high as $8.99 and last traded at $8.96, with a volume of 1,050,912 shares. The stock had previously closed at $8.81.
AFFX has been the subject of a number of recent research reports. Analysts at Maxim Group raised their price target on shares of Affymetrix from $9.00 to $11.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Affymetrix from an “equal weight” rating to an “underweight” rating in a research note to investors on Monday. They now have a $7.20 price target on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of Affymetrix in a research note to investors on Monday, December 2nd. They now have a $10.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $8.53.
Affymetrix has a 1-year low of $3.22 and a 1-year high of $8.90. The stock’s 50-day moving average is $8.34 and its 200-day moving average is $6.39. The company’s market cap is $644.4 million.
Affymetrix (NASDAQ:AFFX) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.02 by $0.03. The company had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.95 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was up 1.0% on a year-over-year basis. Analysts expect that Affymetrix will post $0.13 EPS for the current fiscal year.
Affymetrix, Inc (NASDAQ:AFFX) is engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.